Pending — not yet graded
“Nomura maintains a 'buy' rating on Dr. Reddy's Laboratories with a price target of ₹1,740, implying a 29% upside. The brokerage believes most recent USFDA observations relate to the new facility, suggesting long-standing contamination concerns at the old block may be resolved. The company is optimistic about approvals and drug launches in January-May 2028.”
Nomura Analysis’s track record: 3 graded calls · 95% CI 6–79%
Dr. Reddy's LaboratoriesBullishCalled 29 Jun 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.